Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluarix™ Clear all

Conditions: Influenza
Interventions: Influenza virus vaccine (Fluviral), Saline placebo; Biological
Lead sponsor: ID Biomedical Corporation, Quebec; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Francisco, California • Denver, Colorado + 34 more

Conditions: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
Interventions: Not listed
Lead sponsor: IQuum, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 8
States / cities: Delray Beach, Florida • Savannah, Georgia • Indianapolis, Indiana + 5 more

Conditions: COVID-19, Influenza A, Influenza B
Interventions: COVID/Flu Detect™ Rapid Self-Test; Diagnostic Test
Lead sponsor: InBios International, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Miami, Florida • Boise, Idaho + 5 more

Conditions: Influenza
Interventions: fluID Rapid Influenza Test; Device
Lead sponsor: Nanogen, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 12
States / cities: San Diego, California • DeLand, Florida • Shreveport, Louisiana + 8 more

Conditions: Influenza
Interventions: fluID Rapid Influenza Test, BinaxNOW® Influenza A & B; Device
Lead sponsor: Nanogen, Inc.; Industry
Eligibility: Not listed
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 2
States / cities: Shreveport, Louisiana • Milwaukee, Wisconsin

Conditions: Herpes Zoster
Interventions: Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 829 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania

Conditions: Influenza
Interventions: Influenza; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,847 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 15
States / cities: Clearwater, Florida • Evansville, Indiana • Baltimore, Maryland + 12 more

Conditions: Influenza
Interventions: Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 49 Years
Enrollment: 1,886 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more

Conditions: Influenza
Interventions: FluLaval™ Quadrivalent, Fluzone® Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 35 Months
Enrollment: 2,432 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more

Conditions: Haemophilus Influenzae Type b
Interventions: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 12 Weeks
Enrollment: 4,003 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 63
States / cities: Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more

Conditions: Avian Influenza, Immunisation
Interventions: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 47 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza, Human
Interventions: NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine; Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 1,375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more

Conditions: Influenza
Interventions: Influenza vaccine GSK2321138A, FluarixTM, Influenza vaccine GSK2604409A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 4,659 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 10
States / cities: Chandler, Arizona • Miami, Florida • Newton, Kansas + 7 more

Conditions: Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine
Interventions: GelVac™ nasal powder H5N1 influenza vaccine., Placebo; Drug
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more

Conditions: Influenza
Interventions: Fluarix, GSK Biologicals Influenza Vaccine GSK576389A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 6 more

Conditions: Influenza
Interventions: GSK Bio's influenza vaccine GSK2186877A, Fluarix TM; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 43,695 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 63
States / cities: Alabaster, Alabama • Huntsville, Alabama • Mobile, Alabama + 51 more

Conditions: COVID-19, Influenza A, Influenza B
Interventions: Panbio™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 2 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Vienna, Virginia

Conditions: Influenza
Interventions: Auto-injector for IM/SC vaccine administration; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2006
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Haemophilus Infections, Diphtheria, Tetanus, Polio, Pertussis
Interventions: DTaP-IPV/Hib; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Up to 59 Months
Enrollment: 20,830 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 59
States / cities: Albany, California • Martinez, California • San Francisco, California + 56 more

Conditions: Influenza
Interventions: Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose; Biological
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 944 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Portland, Oregon • Temple, Texas

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel; Diagnostic Test
Lead sponsor: Thermo Fisher Scientific, Inc; Industry
Eligibility: Not listed
Enrollment: 1,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: San Diego, California • Lake City, Florida • Miami, Florida + 13 more

Conditions: Influenza
Interventions: Ear Loop Procedure Mask, 62% Ethyl Alcohol Hand Sanitizer; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,420 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza, Human
Interventions: NanoFlu, Fluzone Quadrivalent; Biological
Lead sponsor: Novavax; Industry
Eligibility: 65 Years and older
Enrollment: 2,654 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 16 more

Search by objective public record fields.

Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.

Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer

Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

Prospective Evaluation of the Fluid Rapid Influenza Test

Comparison of Fluid Rapid Influenza and BinaxNOW Influenza A & B

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Project STARFISH - PRJ0002679

Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission

Phase 3 Pivotal Trial of NanoFlu™ in Older Adults